RDY Stock — Price, Charts & Analysis

Dr. Reddy's Laboratories Limited (RDY) has a trailing P/E of 29.70x and a forward P/E of 18.73x. This places RDY in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

RDY trades with 29.70x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether RDY looks overvalued or undervalued.

RDY's P/E of 29.70x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

RDY's trailing EPS is $0.41 and forward EPS is $0.65. Reported earnings growth is -68.70%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Dr. Reddy's Laboratories Limited generated for each share. RDY's trailing EPS is $0.41, and investors usually prefer EPS that is positive and growing over time.

Dr. Reddy's Laboratories Limited has a market cap of $10.14B, making RDY a large-cap stock based on the current market value shown on Worldtickers.

RDY's latest stock price on Worldtickers is $12.18. The latest move is $0.07 or 0.54%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

RDY's quote includes a latest price of $12.18. The market open is $12.13. Previous close is $12.11. The intraday range is $12.07 to $12.23.

RDY is up in the latest quote, with a move of $0.07 or 0.54%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

RDY generated $331.19B in trailing revenue. Revenue growth is -5.60%, which helps show whether demand is expanding or slowing.

RDY's revenue growth is -5.60%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, RDY shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $33.11B.

Gross margin is 50.18%. Margins show how efficiently Dr. Reddy's Laboratories Limited turns revenue into profit.

Dr. Reddy's Laboratories Limited carries $71.95B and holds $81.43B in cash.

RDY holds $81.43B on its balance sheet.

RDY's book value per share is $0.80.

Yes, Dr. Reddy's Laboratories Limited pays a dividend of $0.08 per share annually. The dividend yield is 69.00%. The payout ratio is 20.19%.

RDY's dividend yield is 69.00%. Its payout ratio is 20.19%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for RDY. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Dr. Reddy's Laboratories Limited's investor relations materials.

RDY's five-year average dividend yield is 72.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 15.90% of RDY shares. Insiders hold 0.00% of shares. Ownership mix helps investors understand how much of Dr. Reddy's Laboratories Limited is held by professional investors and company insiders.

RDY has 833M shares outstanding. Float shares are 3.59B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for RDY, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for RDY is $0.65. Earnings growth is -68.70%. Revenue growth is -5.60%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

RDY's trailing EPS is $0.41. Forward EPS is $0.65. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

RDY is in the Healthcare sector. Its earnings multiple is 29.70x. Its latest displayed growth metric is -5.60%. Compare these figures with sector peers before deciding whether Dr. Reddy's Laboratories Limited is stronger or weaker than average.

RDY trades at $12.18. The stock trades at 29.70x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Dr. Reddy's Laboratories Limited's fundamentals.

RDY risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.24, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

RDY should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 29.70x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Dr. Reddy's Laboratories Limited (RDY) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to bra

RDY trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

RDY stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Dr. Reddy's Laboratories Limited's official website listed on Worldtickers is www.drreddys.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Dr. Reddy's Laboratories Limited employs about 27.53K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Dr. Reddy's Laboratories Limited is headquartered in Hyderabad, India. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

RDY is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

RDY has traded between $11.36 and $15.67 over the past 52 weeks. At $12.18, it is 22.30% below the high and 7.17% above the low. The 52-week range helps gauge long-term price momentum.

RDY is below both its 50-day and 200-day moving averages, which is a common downtrend signal. Its 50-day moving average is $12.88 and its 200-day moving average is $13.45.

RDY's RSI is 44.84. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

RDY's latest RSI reading is 44.84, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for RDY is near $11.58. Key resistance is near $12.58. Breaks above resistance or below support can change the short-term technical setup.

RDY's nearest reported support level is $11.58. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

RDY's nearest reported resistance level is $12.58. A breakout above resistance can improve momentum, especially when volume confirms the move.

RDY trades about 2.57M shares daily on average. The latest displayed volume is 779.01K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

RDY's MACD is 0.05, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

RDY is below both its 50-day and 200-day moving averages, which is a common downtrend signal. RSI is 44.84 (neutral). MACD is bullish. Nearest support is around $11.58. Resistance is around $12.58. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $12.10 (0.66% from price). MA50 is $12.88 (-5.50% from price). MA200 is $13.45 (-9.48% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. RDY's MA20 is $12.10. MA50 is $12.88. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

RDY's pivot is near $12.13. Support is near $11.58. Resistance is near $12.58. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for RDY is near $11.72. The next upper resistance zone is near $12.87. These levels help define risk and possible follow-through zones after a breakout or breakdown.

RDY's Bollinger range is roughly $11.68 to $12.51. Band width is near 6.87%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

RDY's ATR-based typical daily range is about 2.14%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 779.01K shares. Average volume is about 2.57M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

RDY's all-time high shown on Worldtickers is $16.89. Its all-time low is $1.00. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

RDY has a beta of 0.24, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.